八旬高龄患者腹主动脉瘤腔内修复术结局:荟萃分析与系统评价
该系统评价与荟萃分析纳入9项观察性研究、共25723例腹主动脉瘤患者(八旬高龄者5989例,较年轻者19734例),比较EVAR的安全性与有效性。八旬高龄组30天死亡率(2.7% vs 1.5%,p<.001)及中期全因死亡风险(HR 1.946,p<.001)更高,但两组技术成功率无显著差异,随访至5年的再干预率亦无显著差异(HR 1.148,p=.408)。
要点
- 八旬高龄患者EVAR术后30天死亡率为2.7%,高于年轻患者的1.5%(p<.001)。
- 两组技术成功率无显著差异,随访至5年的再干预率亦无显著差异(HR 1.148,p=.408)。
- 在完善术前评估与术后监测的前提下,EVAR仍可作为高龄腹主动脉瘤患者的适宜治疗方式。
核心结论
- 与较年轻患者相比,八旬高龄患者EVAR的围手术期及中期死亡率显著更高,但仍在可接受范围。
- 两组中期再干预率相似,若结合全面术前评估与术后监测,EVAR仍是高龄组的适宜治疗选择。
研究设计与样本
- 采用PRISMA指南,按Cochrane协作网方法评价质量、提取并分析数据。
- 纳入9项比较八旬高龄与较年轻患者EVAR结局的观察性研究,共25723例(八旬高龄5989例,较年轻19734例)。
- 采用固定或随机效应模型,合并计算OR、HR及加权均数差。
- 分析内容为EVAR治疗腹主动脉瘤的短期与中期结局。
主要发现
- 较年轻组男性更多(OR 0.621,p=.002),吸烟者更多(OR 0.457,p<.001)。
- 八旬高龄组手术时间、估计失血量及住院时间均明显更高。
- 八旬高龄组30天死亡率更高(2.7% vs 1.5%,p<.001),内漏、肺部及肾脏疾病亦更多。
- 两组手术技术成功率无显著差异。
- 八旬高龄组中期全因死亡HR明显更高(HR 1.946,p<.001);随访至最长5年的再干预率无显著差异(HR 1.148,p=.408)。
关键数值与推荐
- 八旬高龄组30天死亡率为2.7%,较年轻组为1.5%(p<.001)。
- 中期全因死亡:八旬高龄组HR 1.946(p<.001)。
- 再干预(随访至最长5年):HR 1.148(p=.408),两组无显著差异。
- 男性比例:OR 0.621(p=.002);吸烟:OR 0.457(p<.001)。
临床怎么用
- 对八旬高龄腹主动脉瘤患者,EVAR的围手术期与中期死亡风险高于年轻患者,但幅度可接受。
- 因中期再干预率与年轻患者相似,高龄不应单独作为排除EVAR的依据。
- 选择EVAR前应进行全面的术前评估,术后需纳入规范随访监测。
局限性
- 纳入研究均为观察性研究,证据等级有限。
- 原文未报告各研究的偏倚风险细节及异质性检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This meta-analysis and systematic review aimed to highlight the results of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA) to assess safety and effectiveness in patients older than 80 years of age compared with younger patients. METHODS: PRISMA guidelines were used; quality was appraised, and data were extracted and analysed following the Cochrane collaboration. The MEDLINE and Embase databases were searched on December 31, 2016. All studies related to clinical outcomes following EVAR for AAA treatment in octogenarians compared with those in younger patients were included for a meta-analysis and systematic review of short- and midterm outcomes. Data were analysed using a fixed or random effects model by pooling and calculating odds ratios (ORs) or hazard ratios (HRs) and weighted mean differences, to investigate the safety and feasibility of endoluminal treatment in octogenarians. RESULTS: Published literature search identified nine observational studies, comprising 25,723 patients with AAA (5989 octogenarians and 19,734 younger patients). More males (OR 0.621, p=.002) and smokers (OR 0.457, p<.001) were observed in the younger group. Frequent concomitant diseases were associated with advanced age, thus, the procedural duration, blood loss estimation, and length of stay were considerably higher among octogenarians. Although elderly patients have a higher 30 day mortality (2.7% vs. 1.5%, p<.001), endoleak, pulmonary, and renal diseases, no significant difference was found in the technical success of the procedure. As expected, the HR for octogenarians was markedly higher than that of younger patients (HR 1.946, p<.001) for midterm all-cause mortality. However, the re-intervention rate to maximum follow-up period of 5 years was not significantly different (HR 1.148, p=.408) between the groups. CONCLUSION: Compared with younger patients, EVAR in octogenarians is associated with a significantly higher but still acceptable peri-operative and midterm mortality rate. Because of similar midterm re-intervention rates, these findings suggest that EVAR remains an appropriate therapeutic approach in the elderly group if comprehensive pre-operative evaluation and post-operative surveillance are incorporated.
引用
- Han Y, Zhang S, Zhang J, et al. Outcomes of Endovascular Abdominal Aortic Aneurysm Repair in Octogenarians: Meta-analysis and Systematic Review. Eur J Vasc Endovasc Surg. 2017. PMID: 28822680. doi:10.1016/j.ejvs.2017.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。